Trovagene (TROV) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Trovagene Announces Fourth Quarter and Year End 2015 Financial Results
March 10, 2016 4:14 PM ESTSAN DIEGO, March 10, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:Â TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31, 2015.
"2015 was our coming out year, as the introduction of our liquid biopsy solution for cancer monitoring was met with great response by physicians," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "In support of our commercial efforts, we are assembling a compendium of clinical data, published manuscripts, and case studies in real-world... More
